PandemieGrippaleV1, PubMed, Curation, bibRecord, 000475

Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.

Identifieur interne : 000475 ( PubMed/Curation ); précédent : 000474; suivant : 000476

Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.

Auteurs : Alexander Flood [États-Unis] ; Marcus Estrada [États-Unis] ; David Mcadams [États-Unis] ; Yuhua Ji [États-Unis] ; Dexiang Chen [États-Unis]

Source :

PloS one [ 1932-6203 ] ; 2016.

RBID : pubmed:27851765

Descripteurs français

English descriptors

KwdEn :
- Animals, Chemistry, Pharmaceutical (methods), Crystallization, Crystallography, X-Ray, Excipients, Female, Freeze Drying, Hot Temperature, Humans, Humidity, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (immunology), Influenza, Human (immunology), Mice, Inbred BALB C, Orthomyxoviridae Infections (immunology), Powders, Vaccines, Subunit (immunology).
MESH :
- chemical , immunology : Influenza Vaccines, Vaccines, Subunit.
- chemical : Excipients, Powders.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza, Human, Orthomyxoviridae Infections.
- methods : Chemistry, Pharmaceutical.
- Animals, Crystallization, Crystallography, X-Ray, Female, Freeze Drying, Hot Temperature, Humans, Humidity, Mice, Inbred BALB C.

Abstract

An influenza pandemic remains a major public health concern. A key strategy to prevent a pandemic is to stockpile and pre-position stable influenza vaccine to allow rapid deployment in response to an outbreak. However, most influenza vaccines today are formulated as liquids that are stable only within a temperature range of 2°C to 8°C and require use of a cold chain, making vaccine transportation, distribution, and storage complicated and expensive, particularly for developing countries. To support the National Strategy for Pandemic Influenza preparedness in the United States and internationally, we developed two lead dry formulations of stable H1N1 influenza subunit vaccines using freeze-drying technology. The stable formulations contain an excipient combination of a disaccharide, such as sucrose or trehalose, and glycine, in addition to a surfactant and phosphate buffer. The freeze-dried vaccines were shown to be safe and remained immunogenic in an in vivo study in mice. Moreover, the lead formulations demonstrated no significant loss of activity after 40 months at storage temperatures of 25°C and 37°C. This stability can be particularly attractive as it could eliminate the need to use a cold chain for vaccine deployment and facilitate integration of vaccine distribution with general drug distribution where appropriate. These freeze-dried thermostable influenza subunit vaccines could also reduce the frequency of vaccine stockpile turnover, offering a cost-effective option for pandemic preparedness.

DOI: 10.1371/journal.pone.0164692
PubMed: 27851765

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000475

Links to Exploration step

pubmed:27851765

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.</title>
<author><name sortKey="Flood, Alexander" sort="Flood, Alexander" uniqKey="Flood A" first="Alexander" last="Flood">Alexander Flood</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Estrada, Marcus" sort="Estrada, Marcus" uniqKey="Estrada M" first="Marcus" last="Estrada">Marcus Estrada</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mcadams, David" sort="Mcadams, David" uniqKey="Mcadams D" first="David" last="Mcadams">David Mcadams</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ji, Yuhua" sort="Ji, Yuhua" uniqKey="Ji Y" first="Yuhua" last="Ji">Yuhua Ji</name>
<affiliation wicri:level="1"><nlm:affiliation>Drug Development Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Drug Development Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chen, Dexiang" sort="Chen, Dexiang" uniqKey="Chen D" first="Dexiang" last="Chen">Dexiang Chen</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27851765</idno>
<idno type="pmid">27851765</idno>
<idno type="doi">10.1371/journal.pone.0164692</idno>
<idno type="wicri:Area/PubMed/Corpus">000475</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000475</idno>
<idno type="wicri:Area/PubMed/Curation">000475</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000475</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.</title>
<author><name sortKey="Flood, Alexander" sort="Flood, Alexander" uniqKey="Flood A" first="Alexander" last="Flood">Alexander Flood</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Estrada, Marcus" sort="Estrada, Marcus" uniqKey="Estrada M" first="Marcus" last="Estrada">Marcus Estrada</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mcadams, David" sort="Mcadams, David" uniqKey="Mcadams D" first="David" last="Mcadams">David Mcadams</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ji, Yuhua" sort="Ji, Yuhua" uniqKey="Ji Y" first="Yuhua" last="Ji">Yuhua Ji</name>
<affiliation wicri:level="1"><nlm:affiliation>Drug Development Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Drug Development Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chen, Dexiang" sort="Chen, Dexiang" uniqKey="Chen D" first="Dexiang" last="Chen">Dexiang Chen</name>
<affiliation wicri:level="1"><nlm:affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Devices and Tools Program, PATH, Seattle, Washington</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Chemistry, Pharmaceutical (methods)</term>
<term>Crystallization</term>
<term>Crystallography, X-Ray</term>
<term>Excipients</term>
<term>Female</term>
<term>Freeze Drying</term>
<term>Hot Temperature</term>
<term>Humans</term>
<term>Humidity</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (immunology)</term>
<term>Mice, Inbred BALB C</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Powders</term>
<term>Vaccines, Subunit (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Chimie pharmaceutique ()</term>
<term>Cristallisation</term>
<term>Cristallographie aux rayons X</term>
<term>Excipients</term>
<term>Femelle</term>
<term>Grippe humaine (immunologie)</term>
<term>Humains</term>
<term>Humidité</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Lyophilisation</term>
<term>Poudres</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Température élevée</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins sous-unitaires (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Subunit</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Excipients</term>
<term>Powders</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Infections à Orthomyxoviridae</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins sous-unitaires</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza, Human</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemistry, Pharmaceutical</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Crystallization</term>
<term>Crystallography, X-Ray</term>
<term>Female</term>
<term>Freeze Drying</term>
<term>Hot Temperature</term>
<term>Humans</term>
<term>Humidity</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Chimie pharmaceutique</term>
<term>Cristallisation</term>
<term>Cristallographie aux rayons X</term>
<term>Excipients</term>
<term>Femelle</term>
<term>Humains</term>
<term>Humidité</term>
<term>Lyophilisation</term>
<term>Poudres</term>
<term>Souris de lignée BALB C</term>
<term>Température élevée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An influenza pandemic remains a major public health concern. A key strategy to prevent a pandemic is to stockpile and pre-position stable influenza vaccine to allow rapid deployment in response to an outbreak. However, most influenza vaccines today are formulated as liquids that are stable only within a temperature range of 2°C to 8°C and require use of a cold chain, making vaccine transportation, distribution, and storage complicated and expensive, particularly for developing countries. To support the National Strategy for Pandemic Influenza preparedness in the United States and internationally, we developed two lead dry formulations of stable H1N1 influenza subunit vaccines using freeze-drying technology. The stable formulations contain an excipient combination of a disaccharide, such as sucrose or trehalose, and glycine, in addition to a surfactant and phosphate buffer. The freeze-dried vaccines were shown to be safe and remained immunogenic in an in vivo study in mice. Moreover, the lead formulations demonstrated no significant loss of activity after 40 months at storage temperatures of 25°C and 37°C. This stability can be particularly attractive as it could eliminate the need to use a cold chain for vaccine deployment and facilitate integration of vaccine distribution with general drug distribution where appropriate. These freeze-dried thermostable influenza subunit vaccines could also reduce the frequency of vaccine stockpile turnover, offering a cost-effective option for pandemic preparedness.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27851765</PMID>
<DateCompleted><Year>2017</Year>
<Month>06</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<Issue>11</Issue>
<PubDate><Year>2016</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.</ArticleTitle>
<Pagination><MedlinePgn>e0164692</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0164692</ELocationID>
<Abstract><AbstractText>An influenza pandemic remains a major public health concern. A key strategy to prevent a pandemic is to stockpile and pre-position stable influenza vaccine to allow rapid deployment in response to an outbreak. However, most influenza vaccines today are formulated as liquids that are stable only within a temperature range of 2°C to 8°C and require use of a cold chain, making vaccine transportation, distribution, and storage complicated and expensive, particularly for developing countries. To support the National Strategy for Pandemic Influenza preparedness in the United States and internationally, we developed two lead dry formulations of stable H1N1 influenza subunit vaccines using freeze-drying technology. The stable formulations contain an excipient combination of a disaccharide, such as sucrose or trehalose, and glycine, in addition to a surfactant and phosphate buffer. The freeze-dried vaccines were shown to be safe and remained immunogenic in an in vivo study in mice. Moreover, the lead formulations demonstrated no significant loss of activity after 40 months at storage temperatures of 25°C and 37°C. This stability can be particularly attractive as it could eliminate the need to use a cold chain for vaccine deployment and facilitate integration of vaccine distribution with general drug distribution where appropriate. These freeze-dried thermostable influenza subunit vaccines could also reduce the frequency of vaccine stockpile turnover, offering a cost-effective option for pandemic preparedness.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flood</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Estrada</LastName>
<ForeName>Marcus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McAdams</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ji</LastName>
<ForeName>Yuhua</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Drug Development Program, PATH, Seattle, Washington, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Dexiang</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Devices and Tools Program, PATH, Seattle, Washington, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>11</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005079">Excipients</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011208">Powders</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005079" MajorTopicYN="N">Excipients</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005612" MajorTopicYN="Y">Freeze Drying</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006358" MajorTopicYN="Y">Hot Temperature</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006813" MajorTopicYN="N">Humidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011208" MajorTopicYN="N">Powders</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>We have the following interests. Novartis Pharmaceuticals (East Hanover, NJ) provided the generous supply of two lots of influenza H1N1 subunit bulk vaccine for this study. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>05</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>09</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>11</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>11</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27851765</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0164692</ArticleId>
<ArticleId IdType="pii">PONE-D-16-17769</ArticleId>
<ArticleId IdType="pmc">PMC5112892</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Pharm Sci. 2004 Jul;93(7):1912-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15176078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 2005 Jul;94(7):1427-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15920775</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Pharm. 2015 Apr 10;483(1-2):131-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25660049</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2009 May;8(5):547-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19397412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochim Biophys Acta. 2000 Sep 29;1468(1-2):127-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11018658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2008 Jun;25(6):1256-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18338241</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 2004 Sep;93(9):2259-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15295787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2011 Aug 20;71(12):1591-622</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21861544</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Dec 21;23(6):794-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15542204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Biochem Biophys. 1996 Jul 15;331(2):249-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8660705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2007 Oct;24(10):1883-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17486434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AAPS PharmSciTech. 2005 Sep 30;6(2):E150-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16353972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Pharm. 2000 Aug 10;203(1-2):1-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10967427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Jan 23;24(4):525-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16150515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Dev Technol. 1998 May;3(2):233-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9653761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 1997 Aug;14(8):969-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9279875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharm Sci. 2004 Sep;23 (1):65-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15324924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2004 Feb;21(2):191-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15032301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Aug 29;25(35):6447-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17673338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2011 Oct;63(13):1053-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21756953</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 2002 Apr;91(4):914-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11948529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 1996 Feb;13(2):243-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8932444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 2002 Sep;91(9):1969-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12210044</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2011 Oct;63(13):1118-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21855584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 1989 May 2;28(9):3916-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2526652</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000475 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000475 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27851765
   |texte=   Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27851765" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.

Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki